Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin [IDEC 132] to Patients With Cancer Predominantly Confined to the Peritoneal Cavity

Trial Profile

Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin [IDEC 132] to Patients With Cancer Predominantly Confined to the Peritoneal Cavity

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2005

At a glance

  • Drugs IDEC 132 (Primary)
  • Indications Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top